David Kim
@Paradigm Biocapital Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$2.956BTotal holdings31
Assets growth rate13.13%Assets growth rate (2-Q avg)2.56%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Paradigm Biocapital Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 31 positions.
Assets under management
The assets under management (AUM) of Paradigm Biocapital Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.956B in assets, with a quarterly growth rate of 13.13% and a 2-quarter average growth rate of 2.56%. The portfolio is managed by David Kim, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
SRPTSarepta Therapeutics Inc
| 0% | $149.717M 947,574 shares@ $158.0 avg price | Exited |
CERECerevel Therapeutics Hldng I
| 0% | $95.294M 2.331M shares@ $40.89 avg price | Exited |
ASNDAscendis Pharma A S
| 0% | $90.598M 664,307 shares@ $136.39 avg price | Exited |
XENEXenon Pharmaceuticals Inc
| 0% | $79.667M 2.043M shares@ $38.99 avg price | Exited |
LEGNLegend Biotech Corp
| 0% | $53.295M 1.203M shares@ $44.29 avg price | Exited |
BBIOBridgebio Pharma Inc
| 0% | $27.597M 1.089M shares@ $25.33 avg price | Exited |
VRNAVerona Pharma Plc
| 0% | $10.427M 721,087 shares@ $14.46 avg price | Exited |
ALXOAlx Oncology Hldgs Inc
| 0% | $9.501M 1.576M shares@ $6.03 avg price | Exited |
VORVor Biopharma Inc
| 0% | $6.457M 6.457M shares@ $1.0 avg price | Exited |
ACRVAcrivon Therapeutics Inc
| 0% | $3.826M 659,724 shares@ $5.8 avg price | Exited |